The latest update is out from Argent Biopharma ( (AU:RGT) ).
Argent BioPharma has issued 12,910,884 fully paid ordinary shares under the exemption provided by section 708A(5) of the Corporations Act 2001, allowing the on-sale of these securities without disclosure. This strategic move ensures compliance with relevant legal provisions and maintains transparency, potentially strengthening the company’s market position and investor confidence.
More about Argent Biopharma
Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. The company focuses on developing cannabinoid-based therapeutics and neuroimmune modulation, with a pipeline that includes products like CannEpil®, CogniCann®, and CimetrA® targeting CNS disorders and immune-related conditions.
YTD Price Performance: -20.83%
Average Trading Volume: 554
Technical Sentiment Signal: Buy
Current Market Cap: $6.65M
See more insights into RGT stock on TipRanks’ Stock Analysis page.